Prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome
The new coronavirus infection COVID-19 from the moment of the first message to the present has spread rapidly in more than two hundred countries around the world, posing a serious threat to the life and health of the population. Most patients who have recovered from COVID-19 continue to complain of shortness of breath, increased fatigue, chest pain, palpitations and other symptoms. Currently, the presence of symptoms 12 weeks after the acute phase of the new coronavirus infection COVID-19 is collectively referred to as post-covid syndrome. Studies have shown that this syndrome occurs frequently in recovered patients with COVID-19, regardless of their age and severity of the disease. This feature significantly distinguishes post-covid syndrome from other syndromes after an infection, and therefore the study of the mechanisms of its development, methods of diagnosis and treatment is an important public health problem. Particular attention is paid to patients with comorbidities, especially those with hypertension and cardiovascular diseases, since they have a more severe outcome after infection and higher case mortality rate. The current drug regimens for patients with post-covid syndrome and concomitant diseases are symptomatic. The most common manifestations of post-covid syndrome from the cardiovascular system are an increase in blood pressure and heart rate. In this regard, this review discusses the prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome, accompanied by an increase in blood pressure and heart rate..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
Медицинский совет - (2021), 14, Seite 23-34 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
O. A. Polyakova [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Amlodipine |
|---|
| doi: |
10.21518/2079-701X-2021-14-23-34 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ033746478 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033746478 | ||
| 003 | DE-627 | ||
| 005 | 20230505014254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2021-14-23-34 |2 doi | |
| 035 | |a (DE-627)DOAJ033746478 | ||
| 035 | |a (DE-599)DOAJ674eda102216444fa40bcf6efe054e07 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a O. A. Polyakova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The new coronavirus infection COVID-19 from the moment of the first message to the present has spread rapidly in more than two hundred countries around the world, posing a serious threat to the life and health of the population. Most patients who have recovered from COVID-19 continue to complain of shortness of breath, increased fatigue, chest pain, palpitations and other symptoms. Currently, the presence of symptoms 12 weeks after the acute phase of the new coronavirus infection COVID-19 is collectively referred to as post-covid syndrome. Studies have shown that this syndrome occurs frequently in recovered patients with COVID-19, regardless of their age and severity of the disease. This feature significantly distinguishes post-covid syndrome from other syndromes after an infection, and therefore the study of the mechanisms of its development, methods of diagnosis and treatment is an important public health problem. Particular attention is paid to patients with comorbidities, especially those with hypertension and cardiovascular diseases, since they have a more severe outcome after infection and higher case mortality rate. The current drug regimens for patients with post-covid syndrome and concomitant diseases are symptomatic. The most common manifestations of post-covid syndrome from the cardiovascular system are an increase in blood pressure and heart rate. In this regard, this review discusses the prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome, accompanied by an increase in blood pressure and heart rate. | ||
| 650 | 4 | |a post-covid syndrome | |
| 650 | 4 | |a arterial hypertension | |
| 650 | 4 | |a tachycardia | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a antihypertensive therapy | |
| 650 | 4 | |a bisoprolol | |
| 650 | 4 | |a amlodipine | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a O. D. Ostroumova |e verfasserin |4 aut | |
| 700 | 0 | |a E. V. Mironova |e verfasserin |4 aut | |
| 700 | 0 | |a N. M. Doldo |e verfasserin |4 aut | |
| 700 | 0 | |a A. I. Listratov |e verfasserin |4 aut | |
| 700 | 0 | |a A. V. Filippov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2021), 14, Seite 23-34 |w (DE-627)DOAJ000029483 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g number:14 |g pages:23-34 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2021-14-23-34 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/674eda102216444fa40bcf6efe054e07 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/6389 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2021 |e 14 |h 23-34 | ||